Pharma News

Winter air affects our skin in several ways and makes it dry and itchy. This is when the magical properties of cocoa, banana and mulberry act best by moisturizing skin from deep within, say experts.

A specialised psychotherapy has been linked to changes in activation patterns in certain areas of the brain in patients with borderline personality disorder (BPD), says a study, implying the treatment's impact may go deeper than symptom change.

[adsense:336x280:8701650588]

Combining radiation treatment with 'suicide gene therapy' - a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them - provides an effective two-pronged punch against the disease, new research shows.

• Coartem® Dispersible*, the first WHO prequalified pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries
  
• Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria
  
• Together with other innovations, Coartem® Dispersible contributed to reduce the malaria death rate by 71% for children under the age of 5 years

Rhizen Pharmaceuticals have entered into an exclusive, worldwide license agreement, with Novartis for the development and commercialization of Rhizen’s, inhaled dual PI3K - delta gamma inhibitor and its closely related compounds for  various indications.

Sun Pharma entered into a tripartite research and option agreement with Israel-based Weizmann Institute of Science and Spain’s Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma, a lethal brain cancer.

Teva Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee recommended approval of reslizumab, a humanized anti-interleukin-5 (IL-5) IgG4K monoclonal antibody (mAb), in adult patients aged 18 years and older. Reslizumab is a targeted biologic therapy for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based treatment regimen.

U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy.